Alzheimers Disease
NEJM 362:329-344, Querfurth,H.W. &LaFerla,F.M., 2010
Age, Neuropathology, and Dementia
NEJM 360:2302-2309, Savva,G.M.,et al, 2009
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuropathologic Features of Amnestic Mild Cognitive Impairment
Arch Neurol 63:665-672,645, Petersen,R.C.,et al, 2006
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Clinicopath Conf:Multisystem Neurodegenerative Disease with Dementia Pugilistica
NEJM 340:1269-1277, Case 12-1999, 1999
Clinicopath Conf
Subacute Sclerosing Panencephalitis, Case 15-1998, NEJM 338:1448-1456998., , 1998
Niemann-Pick Disease Type C from Bench to Bedside
JAMA 276:561-564, Schiffmann,R., 1996
Regional Distrib of Neurofibrillary Tangles & Senile Plaques in Cerebral Cortex of Very Old Pts
Arch Neurol 52:1150-1159, Gioannakopoulos,P.,et al, 1995
Apolipoprotein E, Dementia, and Cortical Deposition of B-Amyloid Protein
NEJM 333:1242-1247, 12831995., Polvikoski,T.,et al, 1995
The Neuropathology of Williams Syndrome
Arch Neurol 52:209-212, Golden,J.A.,et al, 1995
Alzheimer's-Disease-Like Changes in Tau Protein Processing:Assoc with Aluminium Accum in Brains of Dialysis Pts
Lancet 343:993-997, 9891994., Harrington,C.R.,et al, 1994
Gerstmann-Straussler-Scheinker Disease, II, Neurofibrillary Tangles & Plaques with PrP-amyloid in an Affected Family
Neurol 39:1453-1461, Ghetti,B.,et al, 1989
Brain Amyloid and Alzheimer Disease
Ann Int Med 109:41-54, Vinters,H.V.,et al, 1988
Immunocytochemistry of Neurofibrillary Tangles in Dementia Pugilistica and Alzheimer's Disease:Evidence for Common Genesis
Lancet 2:1456-1458, Roberts,G.W., 1988
Clinical, Path, & Neurochem Changes in Dementia:Subgroup with Preserved Mental Status & Neocortical Plaques
Ann Neurol 23:138-144, Katzman,R.,et al, 1988
Dementia in Down's Syndrome:Cerebral Glucose Utilization, Neuropsychological Assessment, and Neuropathology
Neurol 38:938-942, Schapiro,M.B.,et al, 1988
Aluminium, Chemical Physiology and Alzheimer's Disease
Lancet 2:1008-1010, Birchall,J.D.&Chappell,J.S., 1988
Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986
Clinicopath. Conference
Subacute Sclerosing Panencephalitis, Due to Measles Virus, Case 25-1986, NEJM 314:1689-170086., , 1986
Neuronal Pathology in the Nucleus Basalis & Associated Cell Groups in Senile Dementia of the Alzheimer's Type
Neurol 35:1089-1095, Saper,C.B.,et al, 1985
The Olfactory Bulbs in Alzheimer's Disease
JNNP 47:56-60, Esiri,M.M.&Wilcock,G.K., 1984
Dementia From Aluminum Pots
NEJM 303:164, Levick,S.E., 1980
Relationship between plaques, tangles, & dementia in Down syndrome
Neurol 30:639-644, Ropper,A.H.,et al, 1980
Dementia in Parkinson Disease:A Neuropathologic Study
Neurol 29:1209-1214, Hakim,A.M.,et al, 1979
Alzheimer Neurofibrillary Tangles in Diseases Other Than Senile & Presenile Dementia
Ann Neurol 5:288-294, Wisniewski,K.,et al, 1979
Presenile Dementia with Lewy Bodies & Neurofibrillary Tangles
Arch Neurol 35:818-822, Forno,L.S.,et al, 1978
Huntington Disease Associated with Alzheimer Disease
Ann Neurol 3:545, McIntosh,G.C.,et al, 1978
Elevated Manganese Levels Associated with Dementia & Extrapyramidal Signs
Neurol 27:213, Banta,R.G.,et al, 1977
Alzheimer Neurofibrillary Change in Subacute Sclerosing Panencephalitis
Ann Neurol 1:103, Mandybur,T.I.,et al, 1977
Epidemiology of Motor-Neuron Diseases
NEJM 288:1047, Bobwick,A.R.,et al, 1973
Alzheimers Disease with Abnormal CSF Flow
Neurol 23:1058, Sohn,R.S.,et al, 1973
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020